Innovations in technology spur treatment of Parkinson’s disease with minimally invasive interventions

Innovations in technology spur treatment of Parkinson’s disease with minimally invasive interventions

Publication date: Apr 14, 2019

Advanced solutions like deep brain stimulation (DBS) are significantly improving the day-to-day experiences for movement disorder patients and reducing the reliance on medication.

On the occasion of World Parkinson’s Day, observed on April 11, health experts have hailed the role of innovations in improving the lives of Parkinson’s Disease (PD) patients.

According to Dr. Guruprasad Hosurkar, Consultant Neurologist and Movement disorder specialist, Columbia Asia Referral Hospital, Bengaluru, Parkinson’s is one of the commonest neurological disorder.

Initially the treatment is essentially medication, but over the time, patients develop complications like shorter duration of good effect, additional involuntary movements, psychiatric side effects, progression of the disease, etc.

The latest systems are engineered for precise neural targeting to customize therapy for patients with Parkinson’s disease.

-We are aware of the special requirements for the Parkinson’s patients and their families,” said Hemraj Singh Parmar, Group CEO BR Life SSNMC Hospital.

Concepts Keywords
Autoimmune Disorders Neurosurgery
Battery Neurological disorder
Bengaluru Ablative brain surgery
Brain Pallidotomy
CEO Thalamotomy
DBS Deep brain stimulation
Deep Brain Stimulation Parkinson’s disease
Dopamine Neurosurgical procedures
India Clinical medicine
Minimally Invasive Medical specialties
Movement Disorder Medicine
Neurodegenerative Disorder Neurodegenerative disorder
Neurological Deep brain stimulation
Neurological Disorder Worldwide neurological disorder
Neurologist Commonest neurological disorder
Neurosurgeon Improvement movement disorder
Pain Pain
Parkinson Neurological symptoms tremors
Rechargeable Batteries Chemical
Special Requirements
Stress

Semantics

Type Source Name
disease MESH Genetic disorders
drug DRUGBANK Nonoxynol-9
disease MESH neurodegenerative disorder
disease MESH lifestyle
disease MESH suffering
disease MESH involuntary movements
disease MESH complications
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT IMPACT
disease MESH movement disorder
gene UNIPROT LRP2
gene UNIPROT MCF2L
gene UNIPROT MAP6
drug DRUGBANK Dopamine
disease MESH neurological disorder
disease MESH tremors

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *